Company intelligence / Profile preview
SupremeCure Pharma
Shanghai, Shanghai, Chinasupremecure.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SupremeCure Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics targeting deubiquitinating enzymes (DUBs). The company leverages its proprietary platform to address unmet medical needs in oncology and immunology, with a primary focus on synthetic lethality and protein homeostasis. Its lead candidate, SC-001, is a potent and selective USP1 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, particularly those with BRCA mutations. SupremeCure aims to provide next-generation precision medicines by modulating the ubiquitin-proteasome system.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SupremeCure Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SupremeCure Pharma.